Glibenclamide 10238-21-8
Glibenclamide , also known as glyburide , is an anti-diabetic drug in a class of medications known as sulfonylureas, closely related to sulfa drugs. It was developed in 1966 in a cooperative study between Boehringer Mannheim (now part of Roche) and Hoechst (now part of sanofi-aventis). It is sold in doses of 1. 25 mg, 2. 5 mg and 5 mg, under the trade names Diabeta, Glynase and Micronase in the United States and Daonil, Semi-Daonil and Euglucon in the United Kingdom. It is also sold in combination with metformin under the trade names Glucovance and Glibomet
.
Uses
It is used in the treatment of type II diabetes. {{As of2007
| Systematic (IUPAC) name: | 5-chloro-N-(4-[N-(cyclohexylcarbamoyl)sulfamoyl]phenethyl)-2-methoxybenzamide |
|---|---|
| Glibenclamide CAS number: | 10238-21-8 |
| ATC code: | A10BB01 |
| PubChem: | 3488 |
| DrugBank: | APRD00233 |
| Formula: | C23 H28 N3 O5 |
| Molecular mass: | 494.004 [[Gram g/mol |
| Glibenclamide Assay/Purity: | Typically NLT 98% |
